Letters to the Editor
3 March 2025
Vol. 77 No. 2 (2025)
https://doi.org/10.4081/reumatismo.2025.1823

After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Polymyalgia rheumatica, immunotherapy, methodology, adverse drug reaction
1131
Views
26
Downloads

Authors

Ciro Manzo
manzoreumatologo@libero.it
https://orcid.org/0000-0002-4800-1817
Internal and Geriatric Medicine Department, Azienda Sanitaria Locale Napoli 3 sud, Rheumatologic Outpatient Clinic, Health District No. 59, Sant’Agnello, Italy.
Marco Isetta
Library and Knowledge Services, Central and North West London NHS Foundation Trust, London, United Kingdom.

Dear Editor,
The number of cases of cancer patients diagnosed as having immune checkpoint inhibitor-mediated polymyalgia rheumatica is increasing...

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Hysa E, Casabella A, Gotelli E, Campitiello R, Schenone C, Genova C, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev 2024; 23: 103589. DOI: https://doi.org/10.1016/j.autrev.2024.103589
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, SchulzeKoops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021; 80: 36-48. DOI: https://doi.org/10.1136/annrheumdis-2020-217139
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981; 30: 239-45. DOI: https://doi.org/10.1038/clpt.1981.154
Manzo C, Natale M, Isetta M, Castagna A. Comment on: immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology 2025; 64: 900-1. DOI: https://doi.org/10.1093/rheumatology/keae259
Manzo C, Isetta M. Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors. Reumatologia 2021; 59: 62-3. DOI: https://doi.org/10.5114/reum.2021.102600

How to Cite



After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?. (2025). Reumatismo, 77(2). https://doi.org/10.4081/reumatismo.2025.1823
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.